Many bioentrepreneurs incorrectly estimate the value of their technology by failing to account adequately for the cost, risk, and time inherent in product development. A researcher has made a ...

The recent volatility of the biotechnology sector markets serves as a stark reminder of the risks and rewards faced by any investor holding equity. However, entrepreneurs, company founders ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange ...

though biotechnology treatments that are approved can have remarkable returns." "There is a high risk of failure for biotech companies, as innovations must undergo years of clinical trials and a ...

In November, we received a $636,000 grant from the USDA’s National Institute of Food and Agriculture’s (NIFA) Biotechnology Risk Assessment Grants (BRAG) program. It will be used to monitor the ...